Ralliant Corporation $RAL Holdings Cut by Bessemer Group Inc.

Bessemer Group Inc. reduced its stake in Ralliant Corporation (NYSE:RAL) by 8.8% in the first quarter, HoldingsChannel.com reports. The fund owned 84,096 shares of the company’s stock after selling 8,085 shares during the quarter. Bessemer Group Inc.’s holdings in Ralliant were worth $3,498,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently made changes to their positions in RAL. Viking Global Investors LP acquired a new stake in shares of Ralliant during the 2nd quarter worth approximately $257,200,000. State Street Corp acquired a new position in Ralliant during the 2nd quarter valued at approximately $213,096,000. Millennium Management LLC boosted its position in Ralliant by 172.4% during the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock valued at $253,175,000 after purchasing an additional 3,147,660 shares during the period. Norges Bank bought a new position in Ralliant during the 4th quarter worth $124,687,000. Finally, Invesco Ltd. grew its stake in Ralliant by 90.1% during the 3rd quarter. Invesco Ltd. now owns 3,871,690 shares of the company’s stock worth $169,309,000 after buying an additional 1,835,128 shares during the last quarter.

Wall Street Analyst Weigh In

RAL has been the topic of a number of recent research reports. BMO Capital Markets began coverage on Ralliant in a research note on Monday. They issued a “market perform” rating and a $78.00 target price on the stock. Morgan Stanley upped their price target on shares of Ralliant from $68.00 to $85.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 23rd. Zacks Research upgraded shares of Ralliant from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, June 30th. Evercore started coverage on shares of Ralliant in a report on Tuesday, June 9th. They issued an “outperform” rating and a $80.00 price objective on the stock. Finally, Oppenheimer lifted their price objective on shares of Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $73.00.

Ralliant Stock Performance

Shares of RAL stock opened at $71.15 on Wednesday. Ralliant Corporation has a 12-month low of $37.27 and a 12-month high of $75.41. The firm has a market capitalization of $7.96 billion and a price-to-earnings ratio of -6.50. The business has a 50 day simple moving average of $65.86 and a 200 day simple moving average of $53.42. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.61 and a quick ratio of 1.05.

Ralliant (NYSE:RAL) last announced its earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.08. The firm had revenue of $534.60 million for the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The firm’s quarterly revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, equities research analysts anticipate that Ralliant Corporation will post 2.64 EPS for the current year.

Ralliant Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th were issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend was Monday, June 8th. Ralliant’s dividend payout ratio (DPR) is -1.83%.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.